Any “savings” from hollowing out early childhood investment will only be deferred to the schoolhouses, courtrooms, emergency ...

CMS cancelled federal marketplace coverage for more than 760,000 people and blocked new agents and brokers from offering ...

If Congress shields self-insured plans from state regulation, it must ensure that federal oversight is strong enough to ...

Members of the Cornell Health Policy Insight Panel had mixed views on whether greater use of reference pricing would lower ...

Each of the several bipartisan bills being considered by Congress to promote biosimilar competition would have major ...

The way to bring down the political temperature is to invest in the one sector where the return may be larger than the ...

Rob Lott and Irene Papanicolas examine how Americans pay for health care through taxes, premiums, and out-of-pocket costs, ...

After a series of losses in constitutional challenges to the Medicare Drug Price Negotiation Program, the drug industry seems to be moving to challenging the program on statutory grounds.

Each of the several bipartisan bills being considered by Congress to promote biosimilar competition would have major implications for the pharmaceutical market.